Er Therapeutics Stock Cash Flow From Operations
| PNGM Stock | USD 0.0001 0.00 0.00% |
Er Therapeutics fundamentals help investors to digest information that contributes to Er Therapeutics' financial success or failures. It also enables traders to predict the movement of PNGM Stock. The fundamental analysis module provides a way to measure Er Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Er Therapeutics stock.
PNGM | Cash Flow From Operations |
Er Therapeutics Company Cash Flow From Operations Analysis
Er Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Er Therapeutics Cash Flow From Operations | (161.43 K) |
Most of Er Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Er Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Er Therapeutics has (161,425) in Cash Flow From Operations. This is 100.03% lower than that of the Metals & Mining sector and significantly lower than that of the Materials industry. The cash flow from operations for all United States stocks is 100.02% higher than that of the company.
PNGM Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Er Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Er Therapeutics could also be used in its relative valuation, which is a method of valuing Er Therapeutics by comparing valuation metrics of similar companies.Er Therapeutics is currently under evaluation in cash flow from operations category among its peers.
PNGM Fundamentals
| Return On Asset | -0.95 | ||||
| Current Valuation | 122.36 K | ||||
| Shares Outstanding | 58.26 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 143,650 X | ||||
| Net Income | (426.95 K) | ||||
| Cash And Equivalents | 650 | ||||
| Total Debt | 48.49 K | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (161.43 K) | ||||
| Beta | 10.4 | ||||
| Market Capitalization | 332.11 K | ||||
| Total Asset | 423.6 K | ||||
| Working Capital | (638 K) | ||||
| Current Asset | 7 K | ||||
| Current Liabilities | 645 K | ||||
| Net Asset | 423.6 K |
About Er Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Er Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Er Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Er Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Er Therapeutics Piotroski F Score and Er Therapeutics Altman Z Score analysis. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.